Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 4—April 2024
Dispatch

Reemergence of Sylvatic Dengue Virus Serotype 2 in Kedougou, Senegal, 2020

Idrissa Dieng1, Maryam Diarra1, Bacary Djilocalisse Sadio, Bocar Sow, Alioune Gaye, Amadou Diallo, Martin Faye, Marie Henriette Dior Ndione, Diawo Diallo, Safietou Sankhe, Mignane Ndiaye, Fode Danfakha, Boly Diop, Amadou Alpha Sall, Gamou Fall, Oumar Faye, Cheikh Loucoubar, Ousmane Faye, Scott C. Weaver, Mawlouth Diallo, Mamadou Aliou Barry1, and Moussa Moise Diagne1Comments to Author 
Author affiliations: Institut Pasteur de Dakar, Dakar, Senegal (I. Dieng, M. Diarra, B.D. Sadio, B. Sow, A. Gaye, A. Diallo, M. Faye, M.H.D. Ndione, D. Diallo, S. Sankhe, M. Ndiaye, A.A. Sall, G. Fall, Oumar Faye, C. Loucoubar, Ousmane Faye, M. Diallo, M.A. Barry, M.M. Diagne); Ministry of Health Kedougou Medical Region, Kedougou, Senegal (F. Danfakha); Ministry of Health Prevention Department, Dakar (B. Diop); University of Texas Medical Branch, Galveston, Texas, USA (S.C. Weaver)

Main Article

Table 1

Epidemiologic and clinical characteristics of suspected and confirmed dengue fever case-patients in study of reemergence of sylvatic DENV serotype 2 in Kedougou, Senegal, 2020*

Patient characteristics Total, n = 300 DENV negative, n = 241 DENV positive, n = 59 p value
Median age, y (IQR)
 25 (14.0–35.0)
 24 (14.0–34.0)
 29 (18.0–33.0)
 0.15†
Age group, y 0.008
<15 75 (25.5) 64 (27.0) 11 (19.3)
15–29 107 (36.4) 89 (37.6) 18 (31.6)
30–45 88 (29.9) 61 (25.7) 27 (47.4)
>45 24 (8.16) 23 (9.70) 1 (1.7)
Unknown
 6 (2.0)
 4 (1.6)
 2 (3.4)
Sex 0.005
F 91 (30.3) 82 (34.0) 9 (15.2)
M
 209 (69.7)
 159 (66.0)
 50 (84.7)
Headache 0.01
No 25 (8.3) 25 (10.4) 0 (0.0)
Yes
 275 (91.7)
 216 (89.6)
 59 (100.0)
Myalgia 0.20
No 150 (50.0) 125 (52.0) 25 (42.4)
Yes
 150 (50.0)
 116 (48.1)
 34 (57.6)
Arthralgia 0.85
No 161 (53.7) 130 (54.0) 31 (52.5)
Yes
 139 (46.3)
 111 (46.0)
 28 (47.5)
Asthenia 0.16
No 252 (84.0) 206 (85.5) 46 (78.0)
Yes
 48 (16.0)
 35 (14.5)
 13 (22.0)
Abdominal pain 0.82
No 262 (87.3) 211 (87.5) 51 (86.4)
Yes
 38 (12.7)
 30 (12.4)
 8 (13.6)
Retroorbital pain 0.77
No 280 (93.3) 224 (93.0) 56 (95.0)
Yes
 20 (6.7)
 17 (7.0)
 3 (5.0)
Vomiting 0.34
No 189 (63.0) 155 (64.3) 34 (57.6)
Yes
 111 (37.0)
 86 (35.7)
 25 (42.4)
Investigated health facilities/regions 0.40
Kedougou health district 90 (30.0) 76 (31.5) 14 (23.7)
Saraya health district 81 (27.0) 63 (26.1) 18 (30.5)
Bandafassi PHC 80 (26.7) 66 (27.4) 14 (24.0)
Military Camp 49 (16.3) 36 (15.0) 13 (22.0)

*Values are no. (%) except as indicated. DENV, dengue virus; IQR, interquartile range; PHC, primary health center. †p value was determined by using the Kruskal-Wallis test; all other p values were determined by using χ2 or Fisher exact tests.

Main Article

1These authors contributed equally to this article.

Page created: February 08, 2024
Page updated: March 20, 2024
Page reviewed: March 20, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external